MiRecule, a biotech startup, has partnered with Sanofi to develop an RNA therapy for facioscapulohumeral muscular dystrophy (FSHD), a rare muscle disorder with no FDA-approved treatments. The company’s platform, DREAmiR, identifies genetic drivers of disease to design RNA therapies. MiRecule also has a head and neck cancer therapeutic candidate, MC-30, which aims to restore tumor suppressing activity lost in some patients. The partnership with Sanofi has brought in $30 million in upfront payments and could earn up to $400 million more. MiRecule is seeking additional funding to support its current programs and develop new ones for other diseases.
Source link
How Startup miRecule Leveraged Its RNA Platform Tech to Land a Sanofi Alliance
